Conventionally, CAR T therapy has demonstrated remarkable success in treating blood cancers such as leukemia and lymphoma by targeting specific, well-defined surface antigens like CD19 on malignant B cells. However, the extension of this approach to solid tumors has been thwarted by two critical hurdles: the lack of a consistently expressed surface antigen across tumor cells and the presence of a dense, immunosuppressive stroma composed of fibroblasts and myeloid cells that inhibit T cell infiltration and function. The new strategy presented by MSK researchers innovatively circumvents these barriers by targeting uPAR, a receptor highly expressed not only on malignant tumor cells but also on the supportive non-malignant cells within the tumor microenvironment.

uPAR is a cell surface receptor implicated in processes related to wound healing and tissue remodeling. In healthy tissues, its expression is limited primarily to myeloid immune cells; however, in the cancerous state, both tumor cells and the adjacent supportive niche cells abnormally upregulate uPAR. This upregulation signifies cellular states associated with malignancy, plasticity, fibrosis, and immunosuppression, thus marking uPAR as a pivotal molecule that orchestrates the tumor’s ecosystem. By leveraging this attribute, the MSK team designed CAR T cells that recognize and eradicate uPAR-positive cells, effectively dismantling the tumor itself and its protective microenvironment concurrently.

The preclinical evaluations, meticulously conducted through an array of cancer cell cultures, xenograft models harboring human tumors, and murine systems mimicking metastasis, demonstrated compelling evidence of the therapeutic potential of these uPAR-directed CAR T cells. Notably, in murine models of ovarian cancer, a notoriously therapy-resistant malignancy, these engineered T cells achieved the remarkable feat of eradicating metastatic lesions, eliciting sustained remission states. Furthermore, the persistence of these CAR T cells provided immunity against tumor rechallenge, highlighting the durability of the antitumor response.

The researchers also illuminated the utility of employing uPAR-targeted CAR T cells as adjunctive therapy post-surgical tumor debulking. In models where surgery alone rendered only temporary disease control, the administration of the CAR T cells significantly eliminated residual cancerous cells, proposing a paradigm shift in integrating cellular therapies with conventional surgical interventions to enhance long-term outcomes.

A profound insight into the molecular underpinnings of uPAR overexpression revealed a correlation with mutations in key oncogenes and tumor suppressors, including p53 and KRAS—mutations frequently encountered in aggressive and treatment-resistant cancers. This molecular association underscores the potential of uPAR-targeted therapy to address hard-to-treat cancers by attacking a common vulnerability linked to critical pathways driving malignancy and cellular plasticity.

Interestingly, the team capitalized on combining the uPAR CAR T cells with senescence-inducing chemotherapeutic agents such as cisplatin, which heighten uPAR expression on tumor cells, thereby enhancing the CAR T cells’ recognition and cytotoxicity. This combinatorial approach not only amplifies therapeutic efficacy but also exploits the dynamic changes within the tumor cell population induced by chemotherapy, addressing cancer’s notorious adaptability.

The innovation extends to molecular engineering sophistication: the designers selected uPAR binders that specifically target a form of the receptor less prone to being shed from the cell surface due to inflammatory signals. This specificity ensures sustained CAR T cell engagement, thereby optimizing the cytotoxic effect and circumventing a common mechanism by which tumors evade immune surveillance.

Crucially, this therapy’s dual-targeting capacity extends beyond malignant cells to encompass tumor-associated fibroblasts and immunosuppressive myeloid cells within the tumor microenvironment. This approach disrupts the cancer-supportive niche—a complex tissue landscape that enables tumor growth, immune evasion, and therapeutic resistance—introducing a multifaceted assault on the tumor ecosystem rather than a unidimensional attack on tumor cells alone.

The conceptual framework of this research is deeply rooted in viewing cancer through the lens of systems biology, recognizing tumors as dynamic ecosystems constituted by cancer cells and their intricate interactions with surrounding stroma and immune cells. Such an ecosystem-centered outlook empowers the development of interventions aimed at perturbing these critical intercellular networks, exemplified by the uPAR-targeted CAR T cells. This strategy reflects the paradigm of the Marie-Josée and Henry R. Kravis Cancer Ecosystems Project at MSK, which promotes innovative therapies by dissecting and targeting these interconnected cellular systems.

Beyond its applications in oncology, the therapeutic implications of targeting uPAR-positive cells extend to various fibrotic, inflammatory, and degenerative diseases wherein similar pathological cell types contribute to disease progression. Therefore, therapies built upon this foundation promise broader biomedical applications, opening new frontiers in treating diseases characterized by aberrant tissue remodeling and inflammation.

Monitoring the disease burden and therapeutic efficacy also benefits from the identification of uPAR-related biomarkers. The team demonstrated the potential of measuring soluble uPAR (suPAR) fragments in the bloodstream and utilizing uPAR-targeted positron emission tomography (PET) imaging to non-invasively visualize tumor presence and treatment response, which could revolutionize real-time disease surveillance and personalized medicine approaches.

The discovery and development of uPAR-targeted CAR T cells signify not only a technical tour de force in immunoengineering but also a conceptual leap in treating solid tumors by simultaneously targeting both the cancer cells and their supportive milieu. As this therapy progresses toward clinical evaluation, it heralds a potentially transformative advancement in cancer treatment modalities, offering hope for overcoming long-standing obstacles in solid tumor immunotherapy.

Subject of Research:
Article Title: A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
News Publication Date: 30-Mar-2026
Web References: https://www.cell.com/cell/fulltext/S0092-8674(26)00269-2, https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/immunotherapy/car-cell-therapy
References: DOI: 10.1016/j.cell.2026.03.002
Image Credits: Memorial Sloan Kettering Cancer Center

Keywords: CAR T cell therapy, uPAR, tumor microenvironment, solid tumors, immunotherapy, cancer biology, cellular senescence, tumor ecosystem, metastatic cancer, molecular oncology, immunoengineering, targeted therapy

Traditional strategies to overcome antigen escape have focused on the genetic redesign of CAR constructs, aiming to improve targeting breadth or affinity. These approaches, although innovative, are often hampered by their complexity, extended timelines, and high production costs, limiting their scalability and clinical applicability. Recognizing these limitations, researchers at the Institute of Process Engineering (IPE), Chinese Academy of Sciences, have pioneered a novel biomimetic platform that enhances CAR T cell therapeutic efficacy without necessitating further genetic modifications.

This breakthrough platform leverages the biomolecular interaction between ferritin—a naturally occurring iron storage protein—and CD71, a transferrin receptor highly expressed on both leukemia cells and autologous CAR T cells. Through meticulous optimization of solvent conditions and assembly parameters, the researchers engineered a ferritin aggregation cell engager (FACE), designed to self-assemble and function as a molecular bridge. FACE simultaneously binds CD71 on CAR T cells and leukemia cells, thereby reinforcing cellular conjugation and potentiating the immunological synapse critical for target recognition and cytotoxicity.

Extensive validation was performed across multiple preclinical models, including patient-derived xenografts (PDX) with diverse leukemia subtypes and refractory disease phenotypes. FACE-enhanced CAR T cells demonstrated therapeutic equivalence to conventional CAR T cells at only one-fifth the cellular dose, significantly reducing the severity of cytokine release syndrome, a common and life-threatening complication of CAR T therapy. Remarkably, in models harboring leukemia cells with antigen expression diminished to below 10% of baseline, FACE-CAR T cells maintained robust antileukemic activity, achieving 100% survival rates—a feat unattainable by standard CAR T approaches.

Further refinement saw the development of a drug-loaded iteration termed FACED, whereby therapeutic agents are encapsulated within the ferritin’s intrinsic cage-like structure. FACED-CAR T cells exhibited enhanced efficacy against high tumor burdens, including antigen-negative leukemia populations responsible for relapse, by combining targeted cell engagement with localized drug delivery. Such innovations suggest a new paradigm wherein biomolecular scaffolds can augment immunotherapy precision and potency.

The significance of these findings extends beyond their therapeutic impact. The FACE platform employs endogenous proteins and FDA-approved polymer derivatives, ensuring biocompatibility and safety. Its straightforward, scalable manufacturing process enables seamless integration within existing CAR T production workflows as a culture supplement, circumventing the need for additional genetic interventions. This adaptability facilitates rapid clinical translation and broad applicability across diverse hematologic malignancies.

Collaborative efforts with clinical partners at Zhujiang Hospital and the Institute of Hematology & Blood Diseases Hospital facilitated robust analyses of patient samples, confirming the ubiquitous overexpression of CD71 across leukemia variants. An AI-assisted predictive framework developed by the research team further enhances the platform’s translational potential by enabling precision forecasting of FACE-mediated therapeutic improvements, enabling patient-specific tailoring of treatment strategies.

The peer review community has heralded this work as a major advance in the field of adoptive T cell therapies. By directly addressing antigen heterogeneity and treatment resistance without additional genetic manipulation, the FACE approach promises to mitigate key barriers currently limiting CAR T cell efficacy. Its modularity and efficacy in resistant leukemia models position it as a transformative tool for improving patient outcomes.

In summary, this novel biomimetic platform represents a paradigm shift in CAR T therapy for leukemia. Through innovative molecular engineering of cell–cell interfaces and strategic drug delivery, it amplifies therapeutic avidity and circumvents antigen escape. Supported by rigorous in vivo and in vitro validation, this strategy holds substantial promise for improving remission durability in relapsed and refractory leukemia. The work exemplifies the power of integrating biomimicry with immunotherapy to devise clinically relevant and scalable solutions to complex oncological challenges.

As the field advances toward increasingly sophisticated cellular therapies, such biomaterial-based enhancements could usher in a new era of precision immunoengineering. By optimizing the spatial and functional dynamics of immune effector and target cells, researchers can unlock previously inaccessible therapeutic avenues, extending hope to patients confronting aggressive and otherwise intractable hematologic malignancies.

Subject of Research:
Not applicable

Article Title:
Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias

News Publication Date:
9-Mar-2026

Web References:
http://dx.doi.org/10.1016/j.cell.2026.02.005

Image Credits:
LI Feng

Keywords:
Leukemia, Blood diseases, Blood cancer, Adoptive T cell therapy, Genetic engineering, Pharmaceuticals